Oramed Issues Letter to Shareholders
Oramed Issues Letter to Shareholders USA - English Share this article Share this article - Clinical Advancements in NASH & Leptin - Discussions with Potential Partners Under Way - To view a video message from the CEO, click here NEW YORK, Jan. 27, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery technology, is pleased to provide the following Letter to Shareholders from Chief Executive Officer Nadav Kidron. Dear Shareholders, We begin 2021 with new hope as va...
Source: prnewswire.com